When a Pregnancy Test Cries Wolf: What the hCG Recall Means for Canadian IVD Licence Holders

A home pregnancy test has one job: give a clear, trustworthy answer at a moment that matters. So when Health Canada announced on 5 October 2026 that a batch of hCG one-step pregnancy tests made by Innovacon Inc. could return false-positive results in people who are not pregnant, the recall landed as more than a product-quality story. It was a reminder that in vitro diagnostic devices, the quiet workhorses of self-testing and point-of-care medicine, carry real regulatory weight in Canada.

For any company that holds a medical device licence, imports a diagnostic, or private-labels a test kit, this recall is a case study in how performance claims, labelling and post-market duties fit together, and in what happens when one of them slips. This article walks through what was recalled, how Canada classifies in vitro diagnostic devices, why a false positive is a performance and labelling failure rather than a simple bad batch, and the problem-reporting and recall clocks you are legally bound to meet.

Executive Summary

On 5 October 2026, Health Canada flagged that certain Innovacon hCG one-step pregnancy tests may detect hCG below the stated assay sensitivity, which can produce false-positive results in non-pregnant individuals. The agency noted that low hCG levels can occur at or after the onset of perimenopause, so users should read results with that in mind. Home pregnancy and fertility tests are near-patient in vitro diagnostic devices, classified as Class II in Canada under the Medical Devices Regulations (SOR/98-282). That class still carries full safety, effectiveness, labelling, problem-reporting and recall obligations.

What Health Canada Recalled, and Why It Matters

What is it? Health Canada issued a recall and public advisory on 5 October 2026 for Innovacon hCG one-step pregnancy tests after identifying that the devices may detect hCG at levels below their stated sensitivity. Why does it matter? A test that reacts to hCG below the level it claims to measure can tell a person they are pregnant when they are not. What should companies do? Treat the recall as a prompt to re-examine your own performance claims, labelling and post-market systems before Health Canada does.

Human chorionic gonadotropin, or hCG, is the hormone a pregnancy test looks for. A reliable test is built around a defined analytical sensitivity, usually expressed in milli-international units per millilitre (mIU/mL), below which it should not report a positive result. When a device reacts below that threshold, it loses the specificity its label promises. Health Canada stated the product "may detect low levels of hCG below the stated assay sensitivity, which may result in false-positive test results in samples from non-pregnant individuals."

The perimenopause angle is the part that makes this recall newsworthy and clinically important. The body can produce small amounts of hCG for reasons unrelated to pregnancy, and Health Canada noted that low hCG levels can occur at or after the onset of perimenopause. A test that is too sensitive at the low end can therefore mislead exactly the users least likely to expect a false alarm.

How In Vitro Diagnostic Devices Are Classified in Canada

What is it? An in vitro diagnostic device, or IVDD, is a medical device that examines samples taken from the body, such as urine, blood or saliva, to provide information about a health condition. Why does it matter? Classification sets the licensing pathway, the evidence you must hold, and the scrutiny you will face. What should companies do? Confirm the class of every diagnostic in your portfolio using Health Canada's risk-based classification rules, and keep the rationale on file.

Canada classifies medical devices, including IVDs, into four risk classes. Class I is the lowest risk and Class IV the highest. The classification is risk-based and rule-driven, set out in the Medical Devices Regulations (SOR/98-282) and explained in Health Canada's Guidance Document for the Risk-based Classification System for In Vitro Diagnostic Devices.

IVDD class	Risk level	Typical examples
Class I	Lowest risk	General-purpose lab reagents, instruments and buffers
Class II	Low public health risk or moderate individual risk	Home pregnancy and fertility tests, cholesterol self-tests, many near-patient kits
Class III	Moderate public health risk or high individual risk	Tests for serious but treatable disease; many near-patient IVDs
Class IV	Highest risk	Tests for life-threatening transmissible agents and donor screening

Home pregnancy tests sit in a specific place in this system. Near-patient IVDs, the family that covers home testing and point-of-care kits, are generally Class III, but Health Canada's classification rules carve out an exception: a near-patient IVDD for the detection of pregnancy or for fertility testing is Class II. The same special rule treats near-patient cholesterol tests as Class II. So an hCG home test is a Class II IVD. That is lower than many diagnostics, but it is not unregulated: a Class II IVD still needs a medical device licence held by the manufacturer, and anyone who imports or distributes it in Canada needs a Medical Device Establishment Licence (MDEL).

If you import or distribute diagnostics, the MDEL Phase II amendments tightened the obligations that sit behind that establishment licence, and the device licence itself must be kept current through the annual medical device licence renewal cycle.

Why a False Positive Is a Performance and Labelling Problem

What is it? A false positive here is a gap between what the device claims it can do and what it actually does at the low end of its measuring range. Why does it matter? Safety and effectiveness requirements in the Medical Devices Regulations require a device to perform as the manufacturer represents. How does it affect compliance? If the label states a sensitivity the device does not reliably meet, both the performance evidence and the labelling are deficient.

Every diagnostic carries an intended use and a set of performance claims: the analyte it detects, the sample type, the sensitivity and specificity, and the conditions under which the result is valid. Those claims are not marketing. They are the technical backbone of the medical device licence application, supported by analytical and, where relevant, clinical performance data. When a device reacts below its stated sensitivity, the real-world performance no longer matches the claim, and the dossier that supported the licence is called into question.

Labelling is the other half of the problem. A home test is used without a clinician, so the label and insert must do the explaining. They must set out the limits of the test clearly, including the known biological factors that can produce a misleading result. Perimenopause is exactly such a factor. A thorough label would warn that low hCG can occur around perimenopause and that an unexpected result should be confirmed with a health professional. A recall often exposes a label that never said enough.

Your Post-Market Duties: Problem Reporting and Recalls

What is it? Mandatory problem reporting and recall rules are the legal clocks that start the moment a manufacturer or importer learns a device may be unsafe or ineffective. Why does it matter? Missing a reporting deadline is itself a compliance failure, separate from the defect that triggered it. What should companies do? Know the timelines, assign the responsibility, and rehearse the process before you need it.

Under the Medical Devices Regulations, a manufacturer or importer must file a mandatory problem report when a device has been associated with an incident. The timeline depends on the severity, as summarised below. These sit alongside the recall duties, which run on their own fast clock.

Obligation	Trigger	Deadline	Reference (SOR/98-282)
Preliminary problem report	Incident led to the death or a serious deterioration in the state of health	Within 10 days of becoming aware	s. 60(1)
Preliminary problem report	Incident could have led to death or serious deterioration were it to recur	Within 30 days of becoming aware	s. 60(1)
Recall decision notice	Manufacturer or importer decides to recall	Within 24 hours of the decision	s. 63.2
Recall information	Recall begins	On or before the day the recall begins	s. 64
Recall results	Recall completed	Within 30 days of completion	s. 65

For a fuller walk-through of what counts as a reportable problem and how the recall process runs, see our guide to medical device recall reporting in Canada and the 24-hour clock. If any of your diagnostics move across the border under a shortage or import measure, the compressed timelines in the three-day device import notification rule add another deadline to track.

Common Inspection Findings and CAPA Lessons

In our audit and gap-assessment work with device and diagnostic companies, the same weaknesses surface again and again when a performance or labelling problem turns into a recall. Treat them as a checklist of where investigators look.

Claims that outrun the data. A stated sensitivity that the validation batches did not consistently achieve, or claims copied from a supplier without independent verification.
Weak complaint handling. User complaints about unexpected positives logged but not trended, so a signal that should have triggered an investigation sat unseen.
Thin labelling of limitations. Inserts that omit known interfering conditions such as perimenopause, recent pregnancy loss, or certain medications.
No clear ownership of reporting clocks. Nobody named as responsible for deciding whether an incident meets the 10-day or 30-day threshold.
Supplier and lot controls that cannot isolate a batch. Incomplete traceability that turns a targeted recall into a broad, costly one.

A sound corrective and preventive action (CAPA) response does more than pull stock. It traces the root cause (for example, a change in antibody reagent lot or a cutoff calibration drift), corrects the labelling and the performance claim, re-validates the affected specification, and feeds the finding back into design and supplier controls so it cannot recur. A recall closed without that loop invites a repeat and a harder conversation at the next inspection.

IVD Compliance Checklist

Use this checklist to pressure-test any diagnostic in your Canadian portfolio.

Confirm the device class using Health Canada's risk-based IVDD classification rules, and keep the written rationale.
Verify that a valid medical device licence is held for the device and that any Canadian importer or distributor holds an MDEL.
Match every labelled performance claim (sensitivity, specificity, sample type, cutoff) to current analytical and clinical performance data.
Check that labels and inserts state the real limits of the test, including biological factors such as perimenopause that can skew results.
Maintain a complaint-handling and trending system that can detect a performance signal early.
Document who decides whether an incident triggers a 10-day or 30-day mandatory problem report, and how.
Keep lot traceability strong enough to isolate an affected batch quickly.
Run a mock recall at least annually and keep the 24-hour recall notice and 30-day results clocks in your procedures.
Align your quality system with ISO 13485 so design, validation and post-market controls connect.

Common Mistakes to Avoid

Treating a Class II test as low-stakes. Lower risk class does not mean lighter duties. Licensing, labelling, reporting and recall rules all still apply.
Copying supplier claims without verification. If you private-label a kit, the claims on your label are yours to defend with your own evidence.
Labelling only the best case. A home test insert that never mentions interfering conditions leaves users, and you, exposed.
Waiting for certainty before reporting. The clock starts when you become aware of an incident, not when the investigation is finished.
Discovering your recall process during the recall. An untested recall plan is where the 24-hour clock is most often missed.

Frequently Asked Questions

Why did Health Canada recall the pregnancy tests?

Health Canada advised that certain Innovacon hCG one-step pregnancy tests may detect hCG below the stated assay sensitivity, which can produce false-positive results in people who are not pregnant. The agency also noted that low hCG levels can occur at or after the onset of perimenopause, which makes a too-sensitive test especially misleading for those users.

Can perimenopause cause a false-positive pregnancy test?

Yes. The body can produce small amounts of hCG for reasons unrelated to pregnancy, and Health Canada noted that low hCG levels can occur at or after the onset of perimenopause. A test that reacts below its stated sensitivity can read these low levels as a positive result, so an unexpected result should be confirmed with a health professional.

How are in vitro diagnostic devices licensed in Canada?

IVDs are classified into four risk classes under the Medical Devices Regulations (SOR/98-282). The manufacturer of a Class II, III or IV device needs a medical device licence from Health Canada, supported by evidence that the device is safe and performs as claimed. Anyone importing or distributing the device in Canada needs a Medical Device Establishment Licence (MDEL).

What class is a home pregnancy test in Canada?

A home pregnancy or fertility test is a Class II in vitro diagnostic device. Near-patient IVDs are generally Class III, but Health Canada's classification rules carve out pregnancy and fertility testing (and near-patient cholesterol testing) as Class II.

How quickly must a device problem be reported to Health Canada?

A manufacturer or importer must file a preliminary mandatory problem report within 10 days of becoming aware of an incident that led to a death or serious deterioration in health, and within 30 days if the incident could have done so were it to recur. A recall decision must be reported to Health Canada within 24 hours.

What should an IVD company do after a recall like this?

Review the performance claims and labelling for every diagnostic you hold, confirm the device class and licensing, strengthen complaint trending, and run a mock recall. A gap assessment that connects your claims, labelling, problem-reporting and recall procedures is the fastest way to find the weak link before an inspector does.

How MFLRC Can Help

MFLRC helps diagnostic and device companies build the evidence and the systems that hold up after a recall, not just before a launch. Our team supports medical device licensing and IVDD classification, labelling and performance-claim review, ISO 13485 and quality-system builds, mandatory problem-reporting and recall procedures, mock recalls, and CAPA programs that close the loop at root cause. Where a problem has already surfaced, our audit and gap-assessment services and regulatory affairs and licensing support help you respond with discipline and defend the decisions you make.

Concerned that your IVD labelling or performance claims would hold up after a recall? Contact MFLRC for a licence and labelling gap review tailored to your products.

Book a consultation with MFLRC

Conclusion

The Innovacon hCG recall is a small device with a large lesson. A diagnostic earns trust by performing exactly as its label says, and it keeps that trust through labelling that tells the truth about its limits and post-market systems that act fast when something slips. For Canadian IVD licence holders, importers and private-labellers, the practical response is straightforward: verify your class, match your claims to your data, label your limits honestly, and rehearse your reporting and recall clocks. Do that, and a competitor's recall becomes your early warning rather than your next headline.